Caitlin Costello
University of California, San Diego
84 Papers
179 Citations
Caitlin Costello is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 19, co-authored 54 publications. Previous affiliations of Caitlin Costello include Ohio State University.
Chat about Author
Papers
Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 trial
P. G. Richardson,William I. Bensinger,Carol Ann Huff,Caitlin Costello,Nikoletta Lendvai,Nikoletta Lendvai,Jesus G. Berdeja,Larry D. Anderson,David S. Siegel,Sundar Jagannath,Jacob P. Laubach,Keith Stockerl-Goldstein,L. Knapp,L. Kwei,Fong Clow,Thorsten Graef,Elizabeth Bilotti,Ravi Vij +17 more
TL;DR: Paul G. Richardson, MD1*, William I. Siegel, MD, PhD9, Sundar Jagannath, MD10, Jacob P. Stockerl-Goldstein, MD11, Lisa Knapp12, Long Kwei, PhD12, Fong Clow, ScD12, Thorsten Graef,MD, PhD 12, Elizabeth Bilotti, MSN12.
2
Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma.
Carolyn Rath,Claude Yoo,Halle Cheplowitz,Mimi Lo,R. Young,Julie Guglielmo,Ila M Saunders,Rahul Banerjee,Richard B Young,Anupama Kumar,Alfred Chung,Aaron S. Rosenberg,Caitlin Costello,Jeffrey R Fine,Machelle D. Wilson,Nimish Patel,Marisela Tan Banez +16 more
TL;DR: In this paper , the authors identify specific clinical predictors of lenalidomide treatment duration that could guide optimal medication management and develop strategies to avoid premature cessation of maintenance in the post-transplant setting.
1
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.
Shaji Kumar,Natalie S. Callander,Melissa Alsina,Djordje Atanackovic,J. Biermann,J. Castillo,Jason C. Chandler,Caitlin Costello,Matthew Faiman,Henry C. Fung,Kelly N. Godby,Craig C. Hofmeister,Leona Holmberg,Sarah Linéa von Holstein,Carol Ann Huff,Yubin Kang,Adetola A. Kassim,Michaela Liedtke,Ehsan Malek,T. Martin,Vishala Neppalli,James L. Omel,Noopur Raje,A. Singhal,George Somlo,Keith Stockerl-Goldstein,Donna M. Weber,Joachim Yahalom,Rashmi Kumar,Dorothy A. Shead +29 more
1
P947: comparative effectiveness of oral ixazomib-lenalidomide-dexamethasone (ird) after initial bortezomib (v)-based induction vs parenteral v-based therapy in newly diagnosed multiple myeloma (ndmm)
Robert M. Rifkin,Caitlin Costello,R E Birhiray,Subbarao Kambhampati,Joshua Richter,Rafat Abonour,H. Lee,Y.J. Kim,Kaili Ren,Dawn Marie Stull,Dasha Cherepanov,Kimberly Bogard,Stephen J. Noga,Saulius Girnius +13 more
TL;DR: The phase IV, community-based, single-arm US MM-6 study is assessing in-class transition (iCT) from V-based induction to all-oral IRd in transplant ineligible NDMM pts treated in routine clinical practice, with the objective of increasing the duration of PI-based treatment while maintaining.
1
Abstract 2414: ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies
Elisa Lazzari,Leslie Crews,Christina C.N. Wu,Heather Leu,Shawn Ali,Raffaella Chiaramonte,Mark D. Minden,Caitlin Costello,Catriona Jamieson +8 more
TL;DR: ADAR1 is identified as a new diagnostic and therapeutic target in MM, and a robust humanized PCL primagraft model is established for future pre-clinical testing of ADAR1 modulatory agents, and may confer a survival and self-renewal advantage to MM cells.